Aidi injection inhibits the migration and invasion of gefitinib-resistant lung adenocarcinoma cells by regulating the PLAT/FAK/AKT pathway

• Published in: Chinese medicine Vol. 20; no. 1; pp. 2 - 21
• Main Authors: Zhang, Jingyuan, Yang, Siyun, Chen, Xiaodong, Zhang, Fanqin, Guo, Siyu, Wu, Chao, Wang, Tieshan, Wang, Haojia, Lu, Shan, Qiao, Chuanqi, Sheng, Xiaoguang, Liu, Shuqi, Zhang, Xiaomeng, Luo, Hua, Li, Qinglin, Wu, Jiarui
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 03.01.2025; BioMed Central; BMC
• Subjects: 1-Phosphatidylinositol 3-kinase; Adenocarcinoma; Aidi injection; AKT protein; Antibodies; Apoptosis; Bioinformatics; Biotechnology; Cancer cells; Cancer therapies; Cell cycle; Cell growth; Cell proliferation; Cellular signal transduction; Combination therapy; Dosage and administration; Drug resistance; Drug therapy; Focal adhesion kinase; Gefitinib; Gefitinib resistance; Health aspects; Injection; Lung cancer; Medical research; Medicine, Chinese; Molecular modelling; Mutation; Non-small cell lung cancer; Non-small cell lung carcinoma; Pancreatic cancer; Pharmacology, Experimental; Physiological aspects; PLAT/FAK/AKT pathway; Proteases; Protein kinases; Small cell lung carcinoma; Toxicity; Traditional Chinese medicine; Transcriptomes; Tumors; China; Beijing China; Aidi injection; PLAT/FAK/AKT pathway; Non-small cell lung cancer; Gefitinib resistance

With extended gefitinib treatment, the therapeutic effect in some non-small cell lung cancer (NSCLC) patients declined with the development of drug resistance. Aidi injection (ADI) is utilized in various cancers as a traditional Chinese medicine prescription. This study explores the molecular mechan...